Vertex researchers awarded 2024 breakthrough prize in life sciences

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that three of its researchers have been awarded the 2024 breakthrough prize in life sciences “for developing life-transforming drug combinations that repair the defective chloride channel protein in patients with cystic fibrosis.” specifically, the award celebrates the work of paul negulescu, ph.d., fredrick van goor, ph.d., and sabine hadida, ph.d., who have worked together to lead cystic fibrosis (cf).
VRTX Ratings Summary
VRTX Quant Ranking